Personalizing treatment in type 2 diabetes: A self-monitoring of blood glucose inclusive innovative approach

Diabetes Technology and Therapeutics

Volumn 14, Issue 4, 2012, Pages 373-378

  Ceriello, Antonio ^a,b   Gallo, Marco ^c   Armentano, Vincenzo ^d   Perriello, Gabriele ^e   Gentile, Sandro ^f   De Micheli, Alberto ^g  

^a INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^b Center of Biomedical Research   (Spain)

^c MOLINETTE HOSPITAL   (Italy)

^d Azienda Local Health Naples 1   (Italy)

^e UNIVERSITY OF PERUGIA   (Italy)

^f SECOND UNIVERSITY OF NAPLES   (Italy)

^g Liguria Regional Health Agency   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE;

AGE; BLOOD GLUCOSE MONITORING; BODY MASS; CHRONIC KIDNEY FAILURE; COMORBIDITY; GLUCOSE BLOOD LEVEL; HUMAN; NON INSULIN DEPENDENT DIABETES MELLITUS; PERSONALIZED MEDICINE; PHENOTYPE; POSTPRANDIAL STATE; PRIORITY JOURNAL; REVIEW; SELF MONITORING;

ALGORITHMS; BLOOD GLUCOSE; BLOOD GLUCOSE SELF-MONITORING; DIABETES MELLITUS, TYPE 2; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERGLYCEMIA; INDIVIDUALIZED MEDICINE; MALE; RISK FACTORS;

EID: 84859371892     PISSN: 15209156     EISSN: 15578593     Source Type: Journal    
DOI: 10.1089/dia.2011.0233     Document Type: Review

References (46)

1. Fajans SS, Cloutier MC, Crowther RL: The Banting Memorial Lecture 1978. Clinical and etiologic heterogeneity of idiopathic diabetes mellitus. Diabetes 1978;27:1112-1125. (Pubitemid 9086671)
2. International Diabetes Federation: Global Guideline for Type 2 Diabetes. www.idf.org (accessed August 29, 2011).
3. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998;352:854-865.
4. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA: 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008;359:1577-1589.
5. Skyler JS, Bergenstal R, Bonow RO, Buse J, Deedwania P, Gale EA, Howard BV, Kirkman MS, Kosiborod M, Reaven P, Sherwin RS; American Diabetes Association; American College of Cardiology Foundation; American Heart Association: Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: A position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association. Diabetes Care 2009;32:187-192.
6. Bruno G, De Micheli A, Frontoni S, Monge L; SID-AMD Working Group on the Standards of Care for Diabetes: Highlights from ''Italian Standards for the Treatment of Diabetes Mellitus 2009-2010.'' Nutr Metab Cardiovasc Dis 2011;21:302-314.
7. DeFronzo RA: Banting Lecture: from the triumvirate to the ominous octet: A new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 2009;58:773-795.
8. Giorda CB: Could clinical inertia in part explain the unexpected association of insulin therapy with poorer cardiovascular outcomes in observational studies on diabetes? Diabetes Res Clin Pract. 2011;92:e47-e48.
9. Smith RJ, Nathan DM, Arslanian SA, Groop L, Rizza RA, Rotter JI: Individualizing therapies in type 2 diabetes mellitus based on patient characteristics: what we know and what we need to know. J Clin Endocrinol Metab 2010;95:1566-1574.
10. Watanabe RM: Drugs, diabetes and pharmacogenomics: The road to personalized therapy. Pharmacogenomics 2011;12: 699-701.
11. Del Prato S, LaSalle J, Matthaei S, Bailey CJ; Global Partnership for Effective Diabetes Management: Tailoring treatment to the individual in type 2 diabetes practical guidance from the Global Partnership for Effective Diabetes Management. Int J Clin Pract 2010;64:295-304.
12. Pozzilli P, Leslie RD, Chan J, De Fronzo R, Monnier L, Raz I, Del Prato S: The A1C and ABCD of glycaemia management in type 2 diabetes: A physician's personalized approach. Diabetes Metab Res Rev 2010;26:239-244.
13. Kruger DF, Boucher JL, Banerji MA: Utilizing current diagnostic criteria and treatment algorithms for managing type 2 diabetes. Postgrad Med 2011;123:54-62.
14. Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, Buse JB, Cushman WC, Genuth S, Ismail-Beigi F, Grimm RH Jr, Probstfield JL, Simons-Morton DG, Friedewald WT: Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358:2545-2559. (Pubitemid 351831356)
15. ADVANCE Collaborative Group, Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, Marre M, Cooper M, Glasziou P, Grobbee D, Hamet P, Harrap S, Heller S, Liu L, Mancia G, Mogensen CE, Pan C, Poulter N, Rodgers A, Williams B, Bompoint S, de Galan BE, Joshi R, Travert F: Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008;358:2560-2572. (Pubitemid 351831357)
16. Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, Zieve FJ, Marks J, Davis SN, Hayward R, Warren SR, Goldman S, McCarren M, Vitek ME, Henderson WG, Huang GD; VADT Investigators: Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009;360:129-139.
17. Del Prato S: Megatrials in type 2 diabetes. From excitement to frustration? Diabetologia 2009;52:1219-1226.
18. Ismail-Beigi F, Moghissi E, Tiktin M, Hirsch IB, Inzucchi SE, Genuth S: Individualizing glycemic targets in type 2 diabetes mellitus: implications of recent clinical trials. Ann Intern Med 2011;154:554-559.
19. Hernandez-Jimenez S, Aguilar-Salinas CA, Mehta R, Rull JA, Gómez-Pérez FJ: Management of type 2 diabetes: more evidence is required to address the clinical and contextual facets. Curr Diabetes Rev 2011;7:99-105.
20. EldorR, Raz I: The individualized targetHbA1c: A newmethod for improving macrovascular risk and glycemia without hypoglycemia and weight gain. Rev Diabet Stud 2009;6:6-12.
21. O'Keefe JH, Abuannadi M, Lavie CJ, Bell DS: Strategies for optimizing glycemic control and cardiovascular prognosis in patients with type 2 diabetes mellitus. Mayo Clin Proc 2011;86:128-138.
22. Italian National Guidelines System. www.snlg-iss.it/(accessed August 29, 2011).
23. Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, Zinman B; American Diabetes Association; European Association for Study of Diabetes: Medical management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009;32:193-203.
24. Adler AI, Shaw EJ, Stokes T, Ruiz F; Guideline Development Group: Newer agents for blood glucose control in type 2 diabetes: summary of NICE guidance. BMJ 2009;338:b1668. doi: 10.1136/bmj.b1668.
25. AMD-SID. Standard italiani per la cura del diabete mellito 2009-2010. www.infodiabetes.it/standard-di-cura/2010-linee-guida.pdf, www.siditalia.it/ documenti/2010-linee-guida. pdf (accessed August 29, 2011).
26. European Diabetes Working Party for Older People 2001-2004: Clinical Guidelines for Type 2 Diabetes Mellitus. www.eugms.org (accessed August 29, 2011).
27. Diabetes Treatment Algorithm from the Diabetes Current Care Guideline. Working Group Set Up by the Finnish Medical Society Duodecim and the Finnish Society of Internal Medicine. www.terveysportti.fi/xmedia/ccs/varhainen- diabetes-en.html (accessed August 29, 2011).
28. Virkamaki A, Saltevo J: Finnish Current Care Guideline for Diabetes: interactive approach to improve individualised treatment. Diabetologia 2011;54:1264-1265.
29. Durán A, Martín P, Runkle I, Pérez N, Abad R, Fernández M, Del Valle L, Sanz MF, Calle-Pascual AL: Benefits of selfmonitoring blood glucose in the management of new-onset Type 2 diabetes mellitus: The St Carlos Study, a prospective randomized clinic-based interventional study with parallel groups. J Diabetes 2010;2:203-211.
30. Polonsky WH, Fisher L, Schikman CH, Hinnen DA, Parkin CG, Jelsovsky Z, Petersen B, Schweitzer M, Wagner RS: Structured self-monitoring of blood glucose significantly reduces A1C levels in poorly controlled, noninsulin-treated type 2 diabetes: results from the Structured Testing Program study. Diabetes Care 2011;34:262-267.
31. Pimazoni-Netto A, Rodbard D, Zanella MT; Diabetes Education and Control Group: Rapid improvement of glycemic control in type 2 diabetes using weekly intensive multifactorial interventions: structured glucose monitoring, patient education, and adjustment of therapy a randomized controlled trial. Diabetes Technol Ther 2011;13:997-1004.
32. Monnier L, Colette C, Lapinski H, Boniface H: Selfmonitoring of blood glucose in diabetic patients: from the least common denominator to the greatest common multiple. Diabetes Metab 2004;30:113-119. (Pubitemid 38715167)
33. Bonomo K, De Salve A, Fiora E, Mularoni E, Massucco P, Poy P, Pomero A, Cavalot F, Anfossi G, Trovati M: Evaluation of a simple policy for pre-and post-prandial blood glucose self-monitoring in people with type 2 diabetes not on insulin. Diabetes Res Clin Pract 2010;87:246-251.
34. IDF Guideline on Self-Monitoring of Blood Glucose in Non-Insulin Treated Type 2 Diabetes. www.idf.org/guidelines/self-monitoring (accessed August 29, 2011).
35. Borkan GA, Norris AH: Assessment of biological age using a profile of physical parameters. J Gerontol 1980;35:177-184. (Pubitemid 10179825)
36. Gerich J: DPP-4 inhibitors: what may be the clinical differentiators? Diabetes Res Clin Pract 2010;90:131-140.
37. Gross JL, Kramer CK, Leitaëo CB, Hawkins N, Viana LV, Schaan BD, Pinto LC, Rodrigues TC, Azevedo MJ; Diabetes and Endocrinology Meta-analysis Group (DEMA): Effect of antihyperglycemic agents added to metformin and a sulfonylurea on glycemic control and weight gain in type 2 diabetes: A network meta-analysis. Ann Intern Med 2011;154:672-679.
38. Waugh N, Cummins E, Royle P, Clar C, Marien M, Richter B, Philip S: Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation. Health Technol Assess 2010;14:1-248.
39. Sharif A: Current and emerging antiglycaemic pharmacological therapies the renal perspective. Nephrology (Carlton) 2011;16:468-475.
40. WorkingGroup on Personalised Therapy in Type 2 Diabetes Set Up by the Italian Association of Medical Diabetologists (AMD). 2011. www.aemmedi.it/ algoritmi/(accessed October 8, 2011).
41. Buse JB: Type 2 diabetes mellitus in 2010: individualizing treatment targets in diabetes care. Nat Rev Endocrinol 2011;7:67-68.
42. Inzucchi SE, McGuire DK: New drugs for the treatment of diabetes: Part II: Incretin-based therapy and beyond. Circulation 2008;117:574-584.
43. Franciosi M, Lucisano G, Pellegrini F, Cantarello A, Consoli A, Cucco L, Ghidelli R, Sartore G, Sciangula L, Nicolucci A; ROSES Study Group: ROSES: role of self-monitoring of blood glucose and intensive education in patients with Type 2 diabetes not receiving insulin. A pilot randomized clinical trial. Diabet Med 2011;28:789-796.
44. Sackett DL, Richardson WS, Rosenberg W, Haynes RB: Evidence-Based Medicine. How to Practice and Teach EBM. New York: Churchill Livingstone, 2000.
45. Bennett WL, Maruthur NM, Singh S, Segal JB, Wilson LM, Chatterjee R, Marinopoulos SS, Puhan MA, Ranasinghe P, Block L, Nicholson WK, Hutfless S, Bass EB, Bolen S: Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinations Ann Intern Med 2011;154:602-613.
46. Bennett WL, Wilson LM, Bolen S, Maruthur N, Singh S, Chatterjee R, Marinopoulos SS, Puhan MA, Ranasinghe P, Nicholson WK, Block L, Odelola O, Dalal DS, Ogbeche GE, Chandrasekhar A, Hutfless S, Bass EB, Segal JB: Oral Diabetes Medications for Adults with Type 2 Diabetes: An Update. Comparative Effectiveness Reviews, No. 27 [Internet]. Agency for Healthcare Research and Quality. 2011. www.ncbi.nlm.nih.gov/books/NBK55754/?part = (accessed August 29, 2011).